{"altmetric_id":12910845,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Rigel Pharmaceuticals"],"first_seen_on":"2016-10-23T09:12:24+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1476964289,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02077192?term=fostamatinib&cond=thrombocytopenia&phase=2&rank=3"],"nct_id":"NCT02077192","pubdate":"2014-02-27T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Open Label Study of R788 in the Treatment of Persistent\/Chronic Immune Thrombocytopenic Purpura (ITP)","type":"clinical_trial_study_record"},"altmetric_score":{"score":7,"score_history":{"1y":7,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":7565447,"mean":6.5306080289211,"rank":1035789,"this_scored_higher_than_pct":85,"this_scored_higher_than":6462733,"rank_type":"exact","sample_size":7565447,"percentile":85},"similar_age_3m":{"total_number_of_other_articles":235257,"mean":12.627225898595,"rank":49906,"this_scored_higher_than_pct":77,"this_scored_higher_than":181975,"rank_type":"exact","sample_size":235257,"percentile":77},"this_journal":{"total_number_of_other_articles":19912,"mean":9.9689002059163,"rank":3244,"this_scored_higher_than_pct":75,"this_scored_higher_than":14944,"rank_type":"exact","sample_size":19912,"percentile":75},"similar_age_this_journal_3m":{"total_number_of_other_articles":780,"mean":7.7159101412067,"rank":74,"this_scored_higher_than_pct":88,"this_scored_higher_than":688,"rank_type":"exact","sample_size":780,"percentile":88}}},"demographics":[],"counts":{"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["seeking_alpha"],"posts_count":1}},"posts":{"news":[{"title":"Rigel's fostamatinib flunks late-stage study in thrombocytopenia due to unexpected responder in placebo group; shares down 29% premarket","url":"http:\/\/ct.moreover.com\/?a=28343089080&p=1pl&v=1&x=rTCv9GLAX6_PAkO3S63gMQ","license":"public","citation_ids":[4705806,12910845],"posted_on":"2016-10-20T11:51:29+00:00","summary":"Micro cap Rigel Pharmaceuticals (NASDAQ: RIGL ) slumps 29% premarket on robust volume in response to its announcement of failed results in the second of two Phase 3 clinical trials assessing fostamatinib for the treatment of adult patients with\u2026","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}}]}}